Our Clinical Trial
is now open!
K36’s lead candidate is KTX-1001, a first-in-class, selective inhibitor of the histone methyltransferase (HMT) MMSET, which is overexpressed in up to 20% of multiple myeloma patients due to the t(4;14) translocation.
We developed KTX-1001 to provide a targeted therapy that specifically addresses the underlying cause of cancer for these multiple myeloma patients. KTX-1001 is the first therapeutic agent to enter the clinic that directly targets overexpression of MMSET.
Creating breakthrough therapies for the unmet medical needs of cancer patients worldwide.
Translating epigenetic modulation of oncogenic pathways into first-in-class small molecule therapeutics.